October 28, 2022

The team's work of MultiplexDX recognized at IT GALA

The new category in every year's ceremony, IT GALA 2022,  recognizing the best technology companies in Slovakia - Nextech magazine readers' award brought another award for MultiplexDX company! In one of the three main categories, Innovation, readers voted based on the question, "Which company or personality contributed the most to managing the Covid-19 pandemic in our country?"

As a society, we do not have to deal with the pandemic these days as much as it was in the past. MultiplexDX company is currently focusing its resources on developing a revolutionary diagnostic test for breast cancer. But at the same time, it is impossible to forget how overwhelming was the period the company went through during the strong pandemic wave.

“My team went on two shifts and worked on weekends and Sundays. They did an incredible job developing one of the market's best PCR tests. Only they know how much of their time, energy, and strength it took. I'm sure you would agree that you might have phenomenal ideas as a leader, but without the right team working on them, those ideas will remain only ideas,”

says Pavol Čekan, co-founder and CEO of MultiplexDX.

The event took place in the Edison park venue in Bratislava, celebrating its 20th anniversary.

About MultiplexDX

MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).

MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.

Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter

Other latest

MultiplexDX News